We are live on ! Find out more
OMIC

Singular Genomics Systems, Inc. Common Stock

Delisted

OMIC was delisted on the 20th of February, 2025.

76 hedge funds and large institutions have $147M invested in Singular Genomics Systems, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 28 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

10% more funds holding

Funds holding: 6976 (+7)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

14% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 28

43% less capital invested

Capital invested by funds: $259M → $147M (-$112M)

Holders
76
Holders Change
+7
Holders Change %
+10.14%
% of All Funds
1.28%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
15
Increased
24
Reduced
28
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
NIP
76
Nicholas Investment Partners
California
-$3.28M -17,330 Closed
CCM
77
Cinctive Capital Management
New York
-$576K -3,043 Closed
Marshall Wace
78
Marshall Wace
United Kingdom
-$111K -582 Closed
PHK
79
Point72 Hong Kong
Hong Kong
-$12K -63 Closed
QT
80
Quantbot Technologies
New York
-$7K -42 Closed
SOW
81
State of Wyoming
Wyoming
-$1K -4 Closed
CS
82
Credit Suisse
Switzerland
+$235 +2 New

OMIC Hedge Fund Activity: Q2 2022 in Review

76 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q2 2022, worth a combined $147M — down 43% from $259M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new OMIC positions and 6 closed out — a net gain of 9 holders — while 24 added to existing stakes and 28 trimmed.

The largest buyer was Tikvah Management, adding an estimated $2.38M. The largest seller was OrbiMed, cutting an estimated $6.88M.

  • 76 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q2 2022, up from 69 in Q1 2022.
  • Funds reported $147M of Singular Genomics Systems, Inc. Common Stock stock for Q2 2022, down 43% quarter-over-quarter.
  • 15 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q2 2022 and 6 closed out, a net change of +9 holders.
  • The largest Singular Genomics Systems, Inc. Common Stock buyer in Q2 2022 was Tikvah Management, an estimated $2.38M added.
  • The largest Singular Genomics Systems, Inc. Common Stock seller in Q2 2022 was OrbiMed, an estimated $6.88M sold.

Based on aggregated 13F filings for Q2 2022.